Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial.
Sybil A McAuleyMelissa H LeeBarbora PaldusSara VogrinMartin I de BockMary B AbrahamLeon A BachMorton G BurtNeale D CohenPeter G ColmanElizabeth A DavisChristel HendrieckxDeborah Jane Holmes-WalkerJoey KayeAnthony C KeechKavita KumareswaranRichard J MacIsaacRoland W McCallumCatriona M SimsProf Jane SpeightStephen N StranksVijaya SundararajanSteven TrawleyGlenn M WardAndrzej S JanuszewskiTimothy W JonesDavid Norman O'Nealnull nullPublished in: Diabetes care (2020)
In adults with type 1 diabetes, 26 weeks of HCL improved TIR, HbA1c, and their sense of satisfaction from managing their diabetes compared with those continuing with user-determined insulin dosing and self-monitoring of blood glucose. For most people living with type 1 diabetes globally, this trial demonstrates that HCL is feasible, acceptable, and advantageous.